Analogs combination therapy in chronic hepatitis B: When and how?;Bithérapie par analogues dans le traitement de l'hépatite chronique B: de novo ou en cas d'échec

Gastroenterologie Clinique et Biologique

Volumn 34, Issue SUPPL. 2, 2010, Pages

  Kahloun, A ^a   Bourliere M ^a   Zoulim, F ^b,c,d  

^a HÔPITAL SAINT JOSEPH   (France)

^b INSERM   (France)

^c UNIVERSITÉ LYON 1   (France)

^d HÔTEL DIEU   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR; CLEVUDINE; ENTECAVIR; LAMIVUDINE; TELBIVUDINE; TENOFOVIR; TENOFOVIR DISOPROXIL;

ARTICLE; CHRONIC HEPATITIS; COMBINATION CHEMOTHERAPY; CROSS RESISTANCE; DISEASE COURSE; EVOLUTION; GENETIC VARIABILITY; HEPATITIS B; HUMAN; VIRUS STRAIN;

ADENINE; ANTIVIRAL AGENTS; DRUG RESISTANCE, VIRAL; DRUG THERAPY, COMBINATION; GUANINE; HEPATITIS B, CHRONIC; HUMANS; LAMIVUDINE; NUCLEOSIDES; PHOSPHONIC ACIDS; PYRIMIDINONES;

EID: 78649353212     PISSN: 03998320     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0399-8320(10)70032-4     Document Type: Article

References (54)

1. Zoulim F., Locarnini S., Hepatitis B. virus resistance to nucleos (t) ide analogues. Gastroenterol 2009, 137:1593-1608. e1-e2.
2. Zoulim F. New insight on hepatitis B virus persistence from the study of intrahepatic viral MLcDNA. J Hepatol 2005, 42:302-308.
3. Zoulim F. Mechanism of viral persistence and resistance to nucleoside and nucleotide analogs in chronic hepatitis B virus infection. Antiviral Res 2004, 64:1-15.
4. Litwin S., Toll E., Jilbert A.R., Mason W.S. The competing roles of virus replication and hepatocyte death rates in the emergence of drug-resistant mutants: theoretical considerations. J Clin Virol 2005, 34(Suppl 1):S96-S107.
5. Fournier C., Zoulim F. Associations thérapeutiques dans la prise en charge des hépatites chroniques B. Gastroenterol Clin Biol 2008, 32:S42-S49.
6. Liaw Y.F., Sung J.J., Chow W.C., Farrell G., Lee C.Z., Yuen H., et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 2004, 351:1521-1531.
7. Villet S., Pichoud C., Villeneuve J.P., Trepo C., Zoulim F. Selection of a multiple drug-resistant hepatitis B virus strain in a livertransplanted patient. Gastroenterol 2006, 131:1253-1261.
8. EASL Clinical Practice Guidelines: management of chronic hepatitis B. J Hepatol 2009, 50:227-242. European Association For The Study Of The Liver.
9. Sung J.J., Lai J.Y., Zeuzem S., Chow W.C., Heathcote E.J., Perrillo R.P., et al. Lamivudine compared with lamivudine and adefovir dipivoxil for the treatment of HBeAg-positive chronic hepatitis B. J Hepatol 2008, 48:728-735.
10. Hui C.K., Zhang H.Y., Bowden S., Locarnini S., Luk J.M., Leung K.W., et al. 96 weeks combination of adefovir dipivoxil plus emtricitabine vs. adefovir dipivoxil monotherapy in the treatment of chronic hepatitis B. J Hepatol 2008, 48:714-720.
11. Lai C.L., Leung N., Teo E.K., Tong M., Wong F., Hann H.W., et al. A 1-year trial of telbivudine, lamivudine, and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B. Gastroenterol 2005, 129:528-536.
12. Liaw Y.F., Lee cm, Akarca U.S., Papatheodoridis G., Wong F., Chang T.T., et al. Interim results of a double blind randomized phase 2 study of the safety of tenofovir disoproxil fumarate, emtricitabine plus tenofovir disoproxil fumarate and entecavir in the treatment of chronic hepatitis B subjects with decompensated liver disease (Abstract). Hepatol 2009, 50(Suppl 4):409A-410A.
13. Villet S., Ollivet A., Pichoud C., Barraud L., Villeneuve J.P., Trepo C., et al. Stepwise process for the development of entecavir resistance in a chronic hepatitis B virus infected patient. J Hepatol 2007, 46:531-538.
14. Fung S.K., Andreone P., Han S.H., Rajender Reddy K., Regev A., Keeffe E.B., et al. Adefovir-resistant hepatitis B can be associated with viral rebound and hepatic decompensation. J Hepatol 2005, 43:937-943.
15. Fung S.K., Chae H.B., Fontana R.J., Conjeevaram H., Marrero J., Oberhelman K., et al. Virologic response and resistance to adefovir in patients with chronic hepatitis B. J Hepatol 2006, 44:283-290.
16. Yeon J.E., Yoo W., Hong S.P., Chang Y.J., Yu S.K., Kim J.H., et al. Resistance to adefovir dipivoxil in lamivudine resistant chronic hepatitis B patients treated with adefovir dipivoxil. Gut 2006, 55:1488-1495.
17. Tenney D.J., Rose R.E., Baldick C.J., Levine S.M., Pokornowski K.A., Walsh A.W., et al. Two-year assessment of entecavir resistance in Lamivudine-refractory hepatitis B virus patients reveals different clinical outcomes depending on the resistance substitutions present. Antimicrob Agents Chemother 2007, 51:902-911.
18. Sherman M., Yurdaydin C., Sollano J., Silva M., Liaw Y.F., Cianciara J., et al. Entecavir for treatment of lamivudine-refractory, HBeAg-positive chronic hepatitis. B. Gastroenterology 2006, 130:2039-2049.
19. Yim H.J., Hussain M., Liu Y., Wong S.N., Fung S.K., Lok A.S. Evolution of multi-drug resistant hepatitis B virus during sequential therapy. Hepatol 2006, 44:703-712.
20. Larrat S., Hilleret M.N., Germi R., Lupo J., Nicod S., Zarski J.P., et al. Sustained virological and biochemical responses to lamivudine and adefovir dipivoxil combination in a chronic hepatitis B infection despite mutations conferring resistance to both drugs. Comp Hepatol 2008, 7:3.
21. Lampertico P., Marzano A., Levrero M., Santantonio T., Di Marco V., Brunetto M., et al. Adefovir and lamivudine combination therapy is superior to adefovir monotherapy for lamivudineresistant patients with HBeAg negative chronic hepatitis B (Abstract). Hepatol 2006, 44(Suppl 1):693A-694A.
22. Rapti I., Dimou E., Mitsoula P., Hadziyannis S.J. Adding-on versus switching-to adefovir therapy in lamivudine-resistant HBeAgnegative chronic hepatitis B. Hepatol 2007, 45:307-313.
23. Pellicelli A.M., Barbaro G., Francavilla R., Romano M., Barbarini G., Mazzoni E., et al. Adefovir and lamivudine in combination compared with adefovir monotherapy in HBeAg-negative adults with chronic hepatitis B virus infection and clinical or virologic resistance to lamivudine: a retrospective, multicenter, nonrandomized, open-label study. Clin Ther 2008, 30:317-323.
24. Gaia S., Barbon V., Smedile A., Olivero A., Carenzi S., Lagget M., et al. Lamivudine-resistant chronic hepatitis B: an observational study on adefovir in monotherapy or in combination with lamivudine. J Hepatol 2008, 48:540-547.
25. Manolakopoulos S., Bethanis S., Koutsounas S., Goulis J., Vlachogiannakos J., Christias E., et al. Long-term therapy with adefovir dipivoxil in hepatitis B e antigen-negative patients developing resistance to lamivudine. Aliment Pharmacol Ther 2008, 27:266-273.
26. Vassiliadis T.G., Giouleme O., Koumerkeridis G., Koumaras H., Tziomalos K., Patsiaoura K., et al. Adefovir plus lamivudine are more effective than adefovir alone in lamivudine-resistant HBeAg- chronic hepatitis B patients: a 4-year study. J Gastroenterol Hepatol 2010, 25:54-60.
27. Chen E.Q., Wang L.C., Lei J., Xu L., Tang H. Meta-analysis: adefovir dipivoxil in combination with lamivudine in patients with lamivudine-resistant hepatitis B virus. Virol J 2009, 6:163.
28. Vigano L., Lampertico P., Lavarone M., Tontini G.E., Facchetti F., Colombo M. High risk of renal impairment and arterial hypertension during long term adefovir and lamivudine combination therapy in patients with lamivudine combination therapy in patients with lamivudine-resistant chronic hepatitis B (Abstract). Hepatol 2008, 48(Suppl 1):708A.
29. Tamori A., Enomoto M., Kobayashi S., Iwai S., Morikawa H., Sakaguchi H., et al. Add-on combination therapy with adefovir dipivoxil induces renal impairment in patients with lamivudinerefractory hepatitis B virus. J Viral Hepat 2010, 17:123-129.
30. Hann H.W., Chae H.B., Dunn S.R. Tenofovir (TDF) has stronger antiviral effect than adefovir (ADV) against lamivudine (LAM) - resistant hepatitis B virus (HBV). Hepatol Int 2008, 2:244-249.
31. Leemans W.F., Janssen H.L., Niesters H.G., de Man R.A. Switching patients with lamivudine resistant chronic hepatitis B virus from tenofovir to adefovir results in less potent HBV-DNA suppression. J Viral Hepat 2008, 15:108-114.
32. van Bommel F., de Man R.A., Wedemeyer H., Deterding K., Petersen J., Buggisch P., et al. Long-term efficacy of tenofovir monotherapy for hepatitis B virus-monoinfected patients after failure of nucleoside/nucleotide analogues. Hepatol 2010, 51:73-80.
33. Reijnders J.G., Deterding K., Petersen J., Zoulim F., Santantonio T., Buti M., et al. Antiviral effect of entecavir in chronic hepatitis B: influence of prior exposure to nucleos (t) ide analogues. J Hepatol 2010, 52:493-500.
34. Lampertico P., Vigano M., Manenti E., Iavarone M., Lunghi G., Colombo M. Adefovir rapidly suppresses hepatitis B in HBeAg-negative patients developing genotypic resistance to lamivudine. Hepatol 2005, 42:1414-1419.
35. Lampertico P., Vigano M., Manenti E., Iavarone M., Sablon E., Colombo M. Low resistance to adefovir combined with lamivudine: a 3-year study of 145 lamivudine-resistant hepatitis B patients. Gastroenterol 2007, 133:1445-1451.
36. Yuen M.F., Sablon E., Hui C.K., Yuan H.J., Decraemer H., Lai C.L. Factors associated with hepatitis B virus DNA breakthrough in patients receiving prolonged lamivudine therapy. Hepatol 2001, 34:785-791.
37. Hadziyannis S.J., Tassopoulos N.C., Heathcote E.J., Chang T.T., Kitis G., Rizzetto M., et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. Gastroenterol 2006, 131:1743-1751.
38. Zeuzem S., Gane E., Liaw Y.F., Lim S.G., DiBisceglie A., Buti M., et al. Baseline characteristics and early on-treatment response predict the outcomes of 2 years of telbivudine treatment of chronic hepatitis B. J Hepatol 2009, 51:11-20.
39. Lai C.L., Shouval D., Lok A.S., Chang T.T., Cheinquer H., Goodman Z., et al. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2006, 354:1011-1020.
40. Chang T.T., Gish R.G., de Man R., Gadano A., Sollano J., Chao Y.C., et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med 2006, 354:1001-1010.
41. Suzuki F., Akuta N., Suzuki Y., Yatsuji H., Sezaki H., Arase Y., et al. Selection of a virus strain resistant to entecavir in a nucleoside- naive patient with hepatitis B of genotype H. J Clin Virol 2007, 39:149-152.
42. Guo J.J., Li Q.L., Shi X.F., Zhang D.Z., Zeng A.Z., Feng T., et al. Dynamics of hepatitis B virus resistance to entecavir in a nucleoside/nucleotide-naive patient. Antiviral Res 2009, 81:180-183.
43. Marcellin P., Heathcote E.J., Buti M., Gane E., de Man R.A., Krastev Z., et al. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med 2008, 359:2442-2455.
44. Lampertico P. Partial virological response to nucleos (t) ide analogues in naive patients with chronic hepatitis B: From guidelines to field practice. J Hepatol 2009, 50:644-647.
45. Safadi R., Xie Q., Chen Y., Yin Y.K., Wei L., Hwang S.G., et al. A randomized trial of switching to telbivudine versus continued lamivudine in adults with chronic hepatitis B: results of the primary analysis at week 24 (Abstract). J Hepatol 2007, 46(Suppl 1):S196-S197.
46. Marcellin P., Buti M., Krastev Z., Gurel S., Balabanska R.I., Dusheiko G., et al. Two year tenofovir disoproxil fumarate treatment and adefovir dipivoxil switch data in HBeAg-negative patients with chronic hepatitis B (study 102), preliminary analysis (Abstract). Hepatol 2008, 48(Suppl 1):370A.
47. Heathcote E.J., Gane E.J., de Man R.A., Chan S., Sievert W., Mauss S., et al. Two year tenofovir dipivoxil fumarate treatment and adefovir dipivoxil switch data in HBeAg- positive partients with chronic hepatitis B (study 103), preliminary results (Abstract). Hepatol 2008, 48(Suppl 1):376A.
48. Nguyen M.H., Trinh H.N., Garcia R.T., Nguyen L.H., Nguyen H.A., Nguyen K.K., et al. treatment outcomes in patients with chronic hepatitis B and partial response to adefovir who were switch to entecavir (Abstract). Hepatol 2008, 48(Suppl 1):711A.
49. Reijnders J.G., Pas S.D., Schutten M., de Man R.A., Janssen H.L. Entecavir shows limited efficacy in HBeAg-positive hepatitis B patients with a partial virologic response to adefovir therapy. J Hepatol 2009, 50:674-683.
50. Chan H.L., Heathcote E.J., Marcellin P., Lai C.L., Cho M., Moon Y.M., et al. Treatment of hepatitis B e antigen positive chronic hepatitis with telbivudine or adefovir: a randomized trial. Ann Intern Med 2007, 147:745-754.
51. Pan C., Hu K.Q. Excellent treatment response to tenofovir monotherapy in chronic hepatitis B patients with prior suboptimal response to entecavir monotherapy (Abstract). Hepatol 2008, 48(Suppl 1):725A.
52. Lampertico P., Vigano M., Facchetti F., Suter F., Minola E.F., Carosi O., et al. Entecavir for NUC-naive chronic hepatitis B patients in clinical practice: long term effectiveness from a large multocenter cohort study in 376 patients (Abstract). Hepatol 2009, 50(Suppl 1):408A.
53. Petersen J., Lütgehetmann M., Zoulim F., Janssen H.L., Sterneck M., Brown A., et al. Safety and efficacy of entecavir and tenofovir combination therapy in hepatitis B patients with previous treatment failures. An international multicenter cohort study (Abstract). J Hepatol 2010, 52(Suppl 1):S394.
54. Sogni P., Nani A., Habersetzer F., Zarski J.P., Hezode C., Bourliere M., et al. Efficacy and safety of the combination of entecavirtenofovir in the treatment of chronic hepatitis B: a nationwide retrospective study (Abstract). J Hepatol 2010, 52(Suppl 1):S396.